Accrued Expenses and Other Current Liabilities (Details Narrative) - Sonnet BioTherapeutics Holdings, Inc. [Member] $ in Millions |
12 Months Ended |
|---|---|
|
Sep. 30, 2024
USD ($)
| |
| Reduced research and development expenses | $ 1.0 |
| Reduced general and administrative expenses | $ 0.9 |